Mybiopassport Launches Personalized Immunity, Sport Performance and Nutrition blood tests
Mybiopassport.com, the platform set-up by CoreMedica Europe, a Swiss biotechnology company with their Swissmedic authorized laboratory based in Geneva, announced today the launch of their “Nutritional Profile” and “Sport Performance Profile” tests, which will complement their current “Immunity Profile” and “COVID-19” tests
Mybiopassport proposes at-home blood collection tests to help anyone become the “heroes of their own health”. Individuals can now collect only a few drops of blood at their homes and send their samples by regular prepaid mail to the company’s authorized laboratory located in Geneva, Switzerland, to determine the levels of key biomarkers known to support sport performance, a healthy nutrition, and the immune system. The tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal through a simple sign-up procedure.
The purposes of these tests are as follows :
- Nutritional– A tool informing the client of their current nutritional status based on past habits and providing personalized recommendations on how to correct any deficiencies or excesses through nutrition. The first of its kind, this test provides information about the levels of micronutrients belonging to all four classes of essential micronutrients, namely vitamins, minerals, fatty acids and amino acids. These are all linked to specific bodily functions (fatigue, sleep, anxiety, etc.) making this test the most comprehensive and informative on the market.
- Sport Performance– A tool developed to help amateur and professional athletes determine if their performance related biomarkers are at their optimal levels to allow them to perform at their best. All the biomarkers tested are linked to specific sport related functions, such as recovery , muscle growth, energy delivery, or even as specific as exercise induced joint pain.
- Immunity- The COVID-19 & Immunity Profile, powered by Mybiopassport, lets clients know if they were previously infected by the SARS-CoV-2 virus through the development of specific antibodies. More importantly, the Immunity Profile test also delivers actionable nutritional recommendations based on a set of key biomarkers known to support the immune system, including vitamin D, zinc and magnesium.
It is now widely accepted that the first step towards a healthy body is good nutrition. Indeed, multiple studies have shown that the risks of developing cardiovascular disease, diabetes, and even dementia are strongly linked to long-term nutritional habits. Recent scientific reports and publications have highlighted the role of nutrition, optimal micronutrient status and a well-functioning immune system as a modifiable factor in reducing the risk of viral infections and their severity. These publications highlight the key role of a good nutritional status for a well-functioning immune system.
Mybiopassport’s mission is clearly to democratize access to specific health-related information and to give people the means to not only understand, but also act on their health through nutrition and lifestyle. They firmly believe in individual empowerment and that the access to personalized health information is the first step towards preventing potential health issues.
Mybiopassport relies on a unique technology in the personalized analysis of biological data on three main axes:
- Pre-analytical with the easy collection of a few drops of blood anywhere, at any time and by anyone,
- Analytical, with the measurement of an unprecedentedly large number of phenotypic biomarkers, via a unique know-how developed over several years,
- Post-analytical, providing not only a scientific result, but personalized recommendations based on a patented technology applied in several fields, such as immunity, nutrition, sport, longevity and anti-aging.
Individuals can now collect a few drops of blood from the comfort and safety of their homes and send their samples by prepaid regular mail to Mybiopassport’s laboratory in Geneva.
The Nutritional, Sport Performance and Immunity tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal with test results reviewed by health professionals.
About CoreMedica Europe:
As a background, BioKaizen, founded in Switzerland and born from developers of the athlete biological passport to detect drug use for the World Anti-Doping Agency and the International Olympic Committee, has developed a mass spectrometry technology platform to identify a person’s nutritional profile using dried blood. Following the merger with BioKaizen in 2018 and its recent acquisition by Swiss Medical Group Holding Luxembourg SA, CoreMedica Europe expanded its offering globally to include personalized nutrition and sport performance information that empowers customers with information to help actively manage their health.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204006231/en/
Contact information
Maximilien Marland
CoreMedica Europe
Tel: +41 78 898 3002
Info@coremedica.ch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release
The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model3.7.2025 13:02:00 EEST | Press release
The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702168211/en/ In 10-20% of tinnitus cases, the noise in the ear is so severe that it significantly impairs the quality of life of those affected. (Source: AI-generated) In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom